Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease

• Published in: JAMA neurology Vol. 70; no. 10; p. 1277
• Main Authors: Kang, Ju-Hee, Irwin, David J, Chen-Plotkin, Alice S, Siderowf, Andrew, Caspell, Chelsea, Coffey, Christopher S, Waligórska, Teresa, Taylor, Peggy, Pan, Sarah, Frasier, Mark, Marek, Kenneth, Kieburtz, Karl, Jennings, Danna, Simuni, Tanya, Tanner, Caroline M, Singleton, Andrew, Toga, Arthur W, Chowdhury, Sohini, Mollenhauer, Brit, Trojanowski, John Q, Shaw, Leslie M
• Format: Journal Article
• Language: English
• Published: United States 01.10.2013
• Subjects: alpha-Synuclein - cerebrospinal fluid; Amyloid beta-Peptides - cerebrospinal fluid; Case-Control Studies; Cohort Studies; Female; Humans; Male; Memory - physiology; Middle Aged; Movement - physiology; Neuropsychological Tests; Parkinson Disease - cerebrospinal fluid; Parkinson Disease - physiopathology; Peptide Fragments - cerebrospinal fluid; Phosphorylation; Regression Analysis; Severity of Illness Index; Statistics as Topic; tau Proteins - cerebrospinal fluid; Threonine - metabolism; Verbal Learning - physiology

We observed a significant correlation between cerebrospinal fluid (CSF) levels of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of CSF biomarkers, as compared with healthy controls, in a cohort of entirely untreated patients with Parkinson disease (PD) at the...